Rezo’s Platform Could ‘Fundamentally Shift’ Drug Discovery

Rezo’s chief technology officer Sourav Bandyopadhyay discusses the company's focus on leveraging AI and machine learning to accelerate drug discovery and its potential for partnerships with big pharma.  

Innovation concept presented by a consultant in management on webinar screen

More from New Science

More from In Vivo